Department of Pathology, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile.
European-Latin American ESCALON Consortium, EU Horizon 2020, Rotterdam, the Netherlands.
Histopathology. 2021 Jul;79(1):2-19. doi: 10.1111/his.14360. Epub 2021 May 6.
Pathological evaluation of gallbladder neoplasia remains a challenge. A significant proportion of cases presents as clinically and grossly inapparent lesions, and grossing protocols are not well established. Among epithelial alterations, pseudo-pyloric gland metaplasia is ubiquitous and of no apparent consequence, whereas goblet cell metaplasia and a foveolar change in surface cells require closer attention. Low-grade dysplasia is difficult to objectively define and appears to be clinically inconsequential by itself; however, extra sampling is required to exclude the possibility of accompanying more significant lesions. For high-grade dysplasia ('high-grade BilIN', also known as 'carcinoma in situ'), a complete sampling is necessary to rule out invasion. Designating in-situ or minimally invasive carcinomas limited to muscularis or above as early gallbladder carcinoma (EGBC) helps to alleviate the major geographical differences (West/East) in the criteria for 'invasiveness' to assign a case to pTis or pT1. Total sampling is crucial in proper diagnosis of such cases. A subset of invasive GBCs (5-10%) arise from the intracholecystic neoplasm (ICN, 'adenoma-carcinoma sequence') category. Approximately two-thirds of ICNs have invasive carcinoma. However, this propensity differs by subtype. True 'pyloric gland adenomas' (> 1 cm) are uncommon and scarcely associated with invasive carcinoma. A distinct subtype of ICN composed of tubular, non-mucinous MUC6 glands [intracholecystic tubular non-mucinous neoplasm (ICTN)] forms a localised pedunculated polyp. Although it is morphologically complex and high-grade, it appears to be invasion-resistant. Some of the invasive carcinoma types in the gallbladder have been better characterised recently with adenosquamous, neuroendocrine, poorly cohesive and mucinous carcinomas often being more advanced and aggressive.
胆囊肿瘤的病理评估仍然是一个挑战。相当一部分病例表现为临床上和大体上无明显病变,且大体检查方案尚未得到很好的建立。在上皮改变中,假幽门腺化生普遍存在且无明显后果,而杯状细胞化生和表面细胞的小凹变化需要更密切关注。低级别异型增生难以客观定义,本身似乎在临床上无足轻重;然而,需要额外取样以排除伴随更严重病变的可能性。对于高级别异型增生(“高级别BilIN”,也称为“原位癌”),需要完整取样以排除浸润的可能性。将局限于肌层或以上的原位或微创癌指定为早期胆囊癌(EGBC)有助于缓解“浸润性”标准的主要地理差异(西方/东方),以将病例分配到 pTis 或 pT1。全面取样对于正确诊断此类病例至关重要。一小部分侵袭性 GBC(5-10%)源自胆囊内肿瘤(ICN,“腺瘤-癌序列”)类别。大约三分之二的 ICN 有浸润性癌。然而,这种倾向因亚型而异。真正的“幽门腺腺瘤”(>1cm)并不常见,几乎与浸润性癌无关。由管状、非黏液性 MUC6 腺体组成的 ICN 独特亚型[胆囊内管状非黏液性肿瘤(ICTN)]形成局部有蒂息肉。尽管它在形态上复杂且高级别,但似乎具有抗浸润性。最近,一些胆囊内的侵袭性癌类型得到了更好的描述,腺鳞癌、神经内分泌癌、黏附性差的癌和黏液癌通常更晚期且更具侵袭性。